“…Animal studies on DOX-chitosan. Clinical studies (mainly lung and breast cancer): chitosan NPs loaded with curcumin, cisplatin or ascorbate [ 77 , 176 ] | Collagen | Conjugation with metal NPs, high biocompatibility, suitable for inhalation, controlled release | Delivery of collagenase desireable in cancer—not possible with collagen, difficult particle fabrication | Research: silver NP stabilized with collagen | [ 177 , 178 ] |
Alginate | Mucoadhesive, pH sensitive, oral delivery, suitable for micelles, stabilizer for metal NPs | Unknown toxicity, need stabilizers | Preclinical studies: magnetic chitosan/alginate- curcumin NP, exemestane-ALG-NPs, paclitaxel-loaded ALG-NP | [ 155 , 156 ] |
Cellulose | pH triggered release, completely biodegradable, oral administration, increase drug solubility | Difficult fabrication, aggregation due to hydrophylic nature, no release in acidic pH (GC), insufficient knowledge about interaction with cells and tissues | Approved: carboxymethyl cellulose. Clinical Trial: eethylcellulose + cetuximab | [ 76 , 179 , 180 ] |
Metal | Se | Antioxidant, anti-inflammatory properties, anticancer activity, dual delivery of therapeutics like siRNA + cisplatin, curcumin SeNPs | Dual role in cancerogenesis and drug delivery—might also produce radicals, possible epigenetical modifications | Only in vitro cell studies | [ 167 , 181 , 182 ] |
Au | High surface to volume ratio, stable, ideal plasmon resonance for therapeutic applications like photothermal and photodynamic therapy, good biosafety profile, high permeability, scalable | Limitations regarding bioavailability of drugs, possible cytotoxicity depending on shape and size, changes in gene expression | Approval: DOX-AuNP, clinical trial: oxaliplatin-platinium-AuNP | [ 183 ] |
|
…”